Mizuho analyst Vikram Malhotra downgraded Sabra Health Care (SBRA) to Neutral from Outperform with an unchanged price target of $20. The firm says multiples in the skilled nursing facility group “reflect a perfect set-up amid higher regulatory risk.” From being outright positive on the group, Mizuho is now neutral.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: